CureMetrix vs Lunit
A screening center buying software for 2D and tomosynthesis reading is the Lunit buyer. The mammography line is INSIGHT MMG (510(k) November 2021, updated April 2026) and INSIGHT DBT (November 2023, updated March 2026), plus Volpara density and positioning tools added through the 2024 acquisition. CureMetrix suits a breast practice that wants calcification reporting from its screening mammograms, or exam scoring for the worklist through cmTriage. Both sell by quote. The two overlap for a center shopping for mammography CAD, and there CureMetrix drops out of the running. Its cmAssist CAD, which third parties describe as marking suspicious areas, is listed as still in development in the US and cleared only in Brazil. A practice adding BAC reporting to existing reads should start with CureMetrix, and a center replacing its reading software should start with Lunit.
Radiology · Reviewed November 2, 2026
CureMetrix
by CureMetrix
AI for mammograms: cmAngio quantifies breast arterial calcification (FDA-cleared), cmTriage prioritizes screening exams.
Lunit
by Lunit · founded 2013
AI for chest X-ray, mammography and breast tomosynthesis, Volpara breast-density tools, and pathology biomarker software (SCOPE).
When to pick each one
CureMetrix
- Quantifies breast arterial calcification, cmAngio V2.July 0, 2026
- cmTriage 510(k) worklist scoring, March 2019
Lunit
- INSIGHT MMG 510(k), updated April 2026
- INSIGHT DBT 510(k), updated March 2026
- Volpara density and positioning tools in the portfolio
Score
Each row shows points earned of points available under the published rubric.
CureMetrix
48of 100
Lunit
66of 100
| Dimension | CureMetrix | Lunit | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 12.7 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 3.9 / 7.8 | 7.8 / 7.8 | -3.9 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
CureMetrix
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. The homepage shows none. |
Lunit
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
CureMetrix
FDA decisions
K260980 (opens in new tab)510(k)2026-07-30
cmAngio V2.0
K250754 (opens in new tab)510(k)2025-04-10
cmAngio V1.6
K232367 (opens in new tab)510(k)2023-10-05
cmAngio V1.0
K183285 (opens in new tab)510(k)2019-03-08
cmTriage
Peer-reviewed
3 PubMed records name CureMetrix.
- A Novel Breast Arterial Calcification Age-Based Percentile Nomogram for the Incremental Prediction of Incidental Cardiovascular Events. (opens in new tab)
- Evaluation of an Artificial Intelligence System for Detection of Invasive Lobular Carcinoma on Digital Mammography. (opens in new tab)
- Multicenter, Multivendor Validation of an FDA-approved Algorithm for Mammography Triage. (opens in new tab)
Lunit
FDA decisions
K260320 (opens in new tab)510(k)2026-04-23
Lunit INSIGHT MMG (v1.1.10)
K253796 (opens in new tab)510(k)2026-03-26
Lunit INSIGHT DBT (V1.2)
K242652 (opens in new tab)510(k)2024-10-04
Lunit INSIGHT DBT v1.1
K231470 (opens in new tab)510(k)2023-11-06
Lunit INSIGHT DBT
K211678 (opens in new tab)510(k)2021-11-17
Lunit INSIGHT MMG
Show 3 more
K211733 (opens in new tab)510(k)2021-11-10
Lunit INSIGHT CXR Triage
K211279 (opens in new tab)510(k)2021-07-27
Volpara Imaging Software
K182310 (opens in new tab)510(k)2018-09-21
Volpara Imaging Software
Peer-reviewed
3 PubMed records name Lunit.
- Comparison of different Lunit INSIGHT CXR software versions when reading chest radiographs for tuberculosis. (opens in new tab)
- Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). (opens in new tab)
- Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | CureMetrix | Lunit |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 2013 |
| HQ | US | KR |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.